Dr. Stephen N. Joffe Files Preliminary Proxy Materials to Elect Three Nominees to TLC Vision’s Board of Directors

CINCINNATI--(BUSINESS WIRE)--Dr. Stephen N. Joffe, a private investor and laser vision correction industry pioneer, today filed preliminary proxy materials with the Securities and Exchange Commission in connection with the nomination of his slate of three highly-qualified and independent candidates (collectively, the “Joffe Group”) for election to the Board of Directors of TLC Vision Corporation (NasdaqGS:TLCV), at the Company's Annual Meeting of shareholders scheduled to be held June 10, 2008. As previously disclosed, Dr. Joffe beneficially owns 5.0% of the outstanding common shares of TLC Vision.

“It is time to transform this underperforming franchise”

TLC Vision operates approximately 80 refractive centers in the U.S. and Canada. Its stock recently traded at a 52-week low of $0.96 per share, down from 52-week high of $6.10 per share.

Dr. Joffe believes that electing the Joffe Group to the Board of Directors presents the best means for TLC Vision’s shareholders to maximize the value of their common shares. In the filing, the Joffe Group states: “Our nominees will work actively to improve the Company’s performance and stock price. In addition, this election contest should send a strong message to the remaining incumbent directors that shareholders are not satisfied with the Company’s recent performance or the decisions made by the Board of Directors.” The Joffe Group further believes that its nominees, if elected, “will bring to TLC Vision significant operational and corporate governance experience and will be in a position to have a positive impact on TLC Vision, bringing to Board deliberations a new voice and perspective of directors who are focused on maximizing shareholder value.”

The Joffe Group nominees include Michael R. Henderson, Cathy Willis and Dr. Joffe.

Dr. Joffe is the founder and past CEO of LCA-Vision, Inc., parent company of LasikPlus, TLC Vision’s largest competitor. Dr. Joffe voluntarily ended his affiliation with Cincinnati-based LCA-Vision, Inc. (Nasdaq: LCAV) in early 2006.

Mr. Henderson also possesses significant refractive industry experience, having served as president and CEO of publicly traded Lasik Vision Corporation from 1996 to 2000.

Ms. Willis is a founder of Felton Willis, LLC, a market research firm that specializes in healthcare-related matters on behalf of both pharmaceutical and consumer products companies. She also offers extensive corporate marketing experience, having served in key managerial positions at P&G.

"It is time to transform this underperforming franchise,” said Dr. Joffe. “TLC Vision shareholders have earned the right to vote in favor of individuals who offer the hands-on experience, perspective and discipline required to fix the company’s broken business model, secure its financial footing and restore shareowner value.”

About Stephen N. Joffe

Stephen N. Joffe, MD, FACS, FCS (SA), FRCS, age 65, is past Chairman of the Board and Chief Executive Officer of LCA Vision. He was the founder of the LCA Vision’s corporate predecessor, Laser Centers of America, Inc. and served as its Chairman of the Board and Chief Executive Officer from its formation in 1985 until its merger into LCA Vision in 1995. In 1983, Stephen Joffe also founded and served as Chairman of Surgical Laser Technologies, Inc. until 1989. He is presently the Chief Executive Officer of the Joffe Foundation, a non-profit charity and Co-Chairman of Joffe MediCenter, LLC, a healthcare services company. In addition, Dr. Joffe is an Esteemed Quondam Professor of Surgery at the University of Cincinnati Medical Center, an honor he has held since 1990. He has held other medical faculty appointments at the Universities of London, Glasgow and Cincinnati and fellowships in the American College of Surgeons and the Royal College of Surgeons of Edinburgh and Glasgow. He has published 170 articles in peer-reviewed and scientific journals and authored 35 chapters for medical books as well as written and edited several books on lasers and their application to medicine and surgery.

About Michael R. Henderson

Michael R. Henderson, age 45, serves as Chairman and Chief Executive Officer of Vancouver, British Columbia-based Moon World Resorts Inc. (MWR), a resort and real estate design company. MWR is responsible for the concept design of what MWR expects to become the world’s largest, most exclusive, mega entertainment complexes currently slated for development in the Middle East’s Gulf region. Prior to co-founding MWR, Mr. Henderson served as President and Chief Executive Officer of Lasik Vision Corporation (LSK:TSXV). Mr. Henderson began his career in the Lasik field as Vice President of Broadway Eye Surgery Center (BESC), an independent privately owned center which was one of the first companies to perform the Lasik procedure. BESC evolved into Lasik Vision Corporation which was one of the first companies to adopt the “direct to consumer” marketing method for laser correction which was later adopted by current industry leader, LCA Vision, and other companies throughout the world. While at Lasik Vision Corporation, Under Mr. Henderson’s leadership from 1997 to 2000, 31 clinics were opened and 28 began development. During May 2000, Mr. Henderson lost a proxy battle at Lasik Vision Corporation started by the company’s co-founder. Mr. Henderson left Lasik Vision Corporation, and the co-founder became Chairman of the Board, Chief Executive Officer and President. Within 10 months after the new board of directors and management group took their positions with Lasik Vision Corporation, the company ceased being publicly traded Prior to co-founding Lasik Vision Corporation, Mr. Henderson held many positions, including Divisional President for Western Canada, with Rentokil Initial Plc (RTO: LSE), one of the world’s largest service companies.

About Cathy Willis

Cathy Willis, age 52, has over 30 years of marketing and marketing research experience, both on the corporate side as a Brand Manager and Marketing Director and as co-founder of Felton Willis, LLC, a qualitative research and strategy development company. Ms. Willis was a Marketing Director in Pharmaceuticals at Procter & Gamble, with direct responsibility for women’s health, GI and anti-infective products. She also had extensive marketing experience at P&G developing targeted marketing programs for a range of consumer products such as diapers, feminine care, skin care, oral care and food/nutritional products. In 1998, Ms. Willis co-founded Felton Willis, LLC. The company offers full-service qualitative research to a range of blue-chip clients, including “Fortune 500” consumer product and pharmaceutical companies. Her focus is primarily on all aspects of health care, both understanding the healthcare consumer and the key medical decision-makers -- MDs, nurses, and managed care professionals. She is a graduate of Miami University with a degree in English/Journalism.

Additional Information

The Joffe Group filed a preliminary proxy statement with the Securities and Exchange Commission on April 4, 2008, containing information about the solicitation of proxies for the 2008 Annual Meeting of the shareholders of the Company.

Investors and security holders of the Company are urged to read the preliminary proxy statement (and, when it becomes available, the definitive proxy statement) because it contains important information. Detailed information relating to the Joffe Group, each member of whom may be deemed to be participants in the solicitation of proxies from Company shareholders, can be found in the preliminary proxy statement filed by the Joffe Group. The preliminary proxy statement and other relevant documents relating to the solicitation of proxies by the Joffe Group are, and the definitive proxy statement will be, available at no charge on the SEC's website at http://www.sec.gov. In addition, the Joffe Group will provide copies of the definitive proxy statement and other relevant documents without charge upon request. Requests for copies should be directed to Innisfree M&A Incorporated at its toll-free number: (888) 750-5834.